通过回顾性临床研究，开展生长抑素类似物（兰瑞肽和奥曲肽）在上海地区用于肢端肥大症术前治疗的药物经济学评价。收集到上海某三甲医院2009年1月1日-2013年6月30日的89例肢端肥大症患者的病史档案资料。研究结果显示，兰瑞肽和奥曲肽用于中国人群的临床疗效(IGF-I水平)控制达标情况相当，且与纯手术组不存在统计学差异；药品干预组的治疗费用明显高于纯手术组，但在干预组中，兰瑞肽组相对于奥曲肽组具有一定的成本优势。%This study evaluated the pharmacoeconomic effect of preoperative treatment of acromegaly in Shanghai by using Octreotide and Lanreotide through retrospective clinical study. The medical records of 89 acromegaly patients in a sampling hospital were collected during January 1, 2009 to June 30, 2013. Both Lanreotide and Octreotide were proven to be effective and fairly equivalence in lowering the level of IGF-I in the preoperative treatment of Chinese patients with acromegaly, and there was no signiifcant difference from the sole surgery group. The costs of treatment per patient of the sole surgery group was obviously lower than those of the drug intervention groups, however, the Lanreotide group had a cost-effective advantage over the Octreotide group.
展开▼
